|NASDAQ: DFFN||Healthcare / Biotechnology / USA|
|5.62||-0.0305||-0.54%||Vol 2.56K||1Y Perf 1 890.14%|
|Mar 24th, 2023 15:57 DELAYED|
|- -||-0.11 -1.95%|
|Target Price||24.75||Analyst Rating||— 0.00|
|Potential %||340.43||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||6.46||Earnings Rating||Strong Buy|
|Market Cap||11.46M||Earnings Date||27th Mar 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|1 Year||1 890.14%|
|3 Years||1 804.27%|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|-26 361 800.00|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Mar 2023|
|Estimated EPS Next Report||-2.20|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||4.38K|
|Avg. Monthly Volume||4.28K|
|Avg. Quarterly Volume||8.14K|
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) stock closed at 5.6195 per share at the end of the most recent trading day (a -0.54% change compared to the prior day closing price) with a volume of 2.56K shares and market capitalization of 11.46M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Diffusion Pharmaceuticals Inc. CEO is Robert Joseph Cobuzzi.
The one-year performance of Diffusion Pharmaceuticals Inc. stock is 1890.14%, while year-to-date (YTD) performance is 11.12%. DFFN stock has a five-year performance of -39.58%. Its 52-week range is between 4.64 and 19.795, which gives DFFN stock a 52-week price range ratio of 6.46%
Diffusion Pharmaceuticals Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 0.46, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -49.18%, a ROC of -48.85% and a ROE of -53.20%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Diffusion Pharmaceuticals Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-2.20 for the next earnings report. Diffusion Pharmaceuticals Inc.’s next earnings report date is 27th Mar 2023.
The consensus rating of Wall Street analysts for Diffusion Pharmaceuticals Inc. is — (0), with a target price of $24.75, which is +340.43% compared to the current price. The earnings rating for Diffusion Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Diffusion Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Diffusion Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 23.72, ATR14 : 0.33, CCI20 : -131.40, Chaikin Money Flow : -0.01, MACD : -0.08, Money Flow Index : 56.56, ROC : -8.23, RSI : 39.27, STOCH (14,3) : 10.74, STOCH RSI : 0.00, UO : 32.61, Williams %R : -89.26), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Diffusion Pharmaceuticals Inc. in the last 12-months were: Jane H. Hollingsworth (Option Excercise at a value of $0), Robert Joseph Cobuzzi (Option Excercise at a value of $0)
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||-||Strong Buy||Strong Buy|
Diffusion Pharmaceuticals Inc is a clinical stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM); Phase II pancreatic cancer; and metastatic brain cancer.
CEO: Robert Joseph Cobuzzi
Telephone: +1 434 220-0718
Address: 1317 Carlton Avenue, Charlottesville 22902, VA, US
Number of employees: 10
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.